Rivernorth Capital Management’s Revelation Biosciences Warrant REVBW Stock Holding History

Rivernorth Capital Management’s Portfolio REVBW Stock Details REVBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200,000	Closed	-$136K	–	840
2021 Q4	$136K	Hold	200,000	–	–	0.01%	478
2021 Q3	$122K	Hold	200,000	–	–	0.01%	390
2021 Q2	$128K	Hold	200,000	–	–	0.01%	384
2021 Q1	$104K	Buy	200,000 +3,382	+2%	+$3.16K	0.01%	355
2020 Q4	$175K	Buy	+196,618	New	+$134K	0.01%	272

Other funds holding REVBW

OCAM

Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Capstone Investment Advisors New York $54B AUM 23.5% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Rivernorth Capital Management's REVBW Position: Q1 2022 in Review

Rivernorth Capital Management sold out of Revelation Biosciences Warrant (REVBW) in Q1 2022, closing a stake of 200,000 shares — an estimated $136K sold.

Rivernorth Capital Management first reported a position in REVBW in Q4 2020 and held it in 5 quarters. The position peaked at $175K in Q4 2020. 18 funds tracked by Wall St. Rank hold REVBW as of Q1 2022.

Rivernorth Capital Management reported no remaining Revelation Biosciences Warrant position as of Q1 2022 after selling out during the quarter.
Rivernorth Capital Management sold 200,000 Revelation Biosciences Warrant shares in Q1 2022, an estimated $136K.
Rivernorth Capital Management first reported a position in Revelation Biosciences Warrant in Q4 2020 and held it in 5 quarters.
Rivernorth Capital Management's Revelation Biosciences Warrant position peaked at $175K in Q4 2020.
18 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q1 2022.

Based on Rivernorth Capital Management's 13F filing for Q1 2022, filed 16 May 2022.